Eidos starts Phase III of AG10 in TTR amyloid cardiomyopathy

Eidos Therapeutics Inc. (NASDAQ:EIDX) began the two-part Phase III ATTRibute-CM trial evaluating AG10 to treat transthyretin (TTR) amyloidosis cardiomyopathy.

The primary endpoint for the first part of the trial is the change from baseline in 6-minute walk distance (6MWD) at 12 months. For the second part, the primary endpoint is evaluating all-cause mortality and the frequency of cardiovascular-related hospitalizations at 30 months...